Prosecution Insights
Last updated: May 04, 2026
Application No. 18/049,464

Method for Preparing a Three-Dimensional Scaffold for Medical Use

Non-Final OA §112
Filed
Oct 25, 2022
Priority
May 01, 2020 — DK PA202000521 +1 more
Examiner
DESAI, ANAND U
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Askel Heathcare Ltd.
OA Round
4 (Non-Final)
79%
Grant Probability
Favorable
4-5
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
712 granted / 900 resolved
+19.1% vs TC avg
Moderate +12% lift
Without
With
+11.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
31 currently pending
Career history
931
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
18.1%
-21.9% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
34.8%
-5.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 900 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This office action is in response to the Patent Trail and Appeal Board decision. Withdrawal of Rejection(s) The rejection of claims 1, 2, 4, 6, 7, 9, 10, 12, 13, 14, 15, 16, 17, 19, 20 on the ground of provisional nonstatutory double patenting as being unpatentable over claims 14, 15, and 18 of copending Application No. 17/518,157 (reference application) (US 2022/0054703 A1; previously cited) in view of Holy et al (US 2003/0008395 A1) is withdrawn based on the abandonment of the copending application. The rejection of claim(s) 1, 2, 4, 6, 7, 9, 10, 12-18, 20-22, and 24 under 35 U.S.C. 103 as being unpatentable over Haaparanta et al. (10/25/2022 IDS, NPL #4; previously cited) in view of Holy et al (US 2003/0008395 A1) is withdrawn based on the analysis that Holy does not sufficiently establish that a polymer that has been surface modified with collagen has been sterilized with gamma-irradiation after that modification as stated in the Patent Trail and Appeal Board decision. Information Disclosure Statement The information disclosure statements (IDSs) submitted on August 13, 2024, December 2, 2024, and May 8, 2025 are being considered by the examiner. The signed IDS forms are attached with the instant office action. Pending Rejection(s) Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 19 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 19 is written as dependent on claim 17, but then refers to a limitation on claim 18 from which it does not properly depend. The reference to claim 18 in claim 19 is unclear as it lacks proper dependency. Any dependent claim which refers to more than one other claim (“multiple dependent claim”) shall refer to such other claims in the alternative only. Furthermore claim 19 is drawn to a “method of claim 17 wherein the mesh in step iii) of claim 18 is subjected to…”. However, claim 18 does not recite “a step iii)” either. So, claim 19 is not only improperly dependent but also lacks antecedence. Examiner suggests amending claim 19 to properly depend from claim 17 which does recite “step iii)”. Conclusion Claim 19 is rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANAND U DESAI whose telephone number is (571)272-0947. The examiner can normally be reached 9:00-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Show 16 earlier events
Jan 08, 2025
Response after Non-Final Action
Jan 22, 2025
Response after Non-Final Action
Mar 31, 2025
Response after Non-Final Action
Mar 31, 2025
Response after Non-Final Action
Apr 01, 2025
Response after Non-Final Action
Apr 01, 2025
Response after Non-Final Action
Jan 22, 2026
Response after Non-Final Action
Apr 18, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600754
Protein Fiber Production Method
5y 0m to grant Granted Apr 14, 2026
Patent 12594346
CROSSLINKED HYDROGEL FOR IMMUNE CHECKPOINT BLOCKADE DELIVERY
3y 2m to grant Granted Apr 07, 2026
Patent 12595441
AUTOMATIC DISHWASHING COMPOSITION COMPRISING A PROTEASE
3y 3m to grant Granted Apr 07, 2026
Patent 12582703
BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHOGS OF MAKING
3y 4m to grant Granted Mar 24, 2026
Patent 12577354
METHODS AND COMPOSITIONS FOR SYNTHESIZING IMPROVED SILK FIBERS
3y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
79%
Grant Probability
91%
With Interview (+11.8%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 900 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month